LENZ LENZ Therapeutics, Inc.
USHealthcareAs of 2026-07-10 16:00
Why LENZ matters now
LENZ Therapeutics, Inc. (LENZ) is a US stock in Healthcare. The latest InvestLog snapshot shows $5.59 with -3.45% on the session and $175.3M in market capitalization; recent performance reads 1-month -7.52% and YTD -61.56%.
The latest financial table shown here is Q1 2026, with revenue of $1.9M, net income of $-41.5M, and EPS of $-1.32. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -45.3%.
The latest indexable market news headline is "LENZ Therapeutics Announces Launch of New Telehealth Prescribing Option to Accelerate Patient Access to VIZZ® for the Treatment of Presbyopia" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $12.00; recent insider activity includes Scheiner Zachary filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.78
P/S
9.19
EV/EBITDA
-1.56
DCF Value
$2.57
FCF Yield
-45.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
91.2%
Operating Margin
-563.8%
Net Margin
-519.3%
ROE
-46.8%
ROA
-40.0%
ROIC
-47.9%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $1.9M | $-41.5M | $-1.32 |
| Q4 2025 | $1.6M | $-35.9M | $-1.16 |
| FY 2025 | $19.1M | $-82.1M | $-2.85 |
| Q3 2025 | $12.5M | $-16.7M | $-0.59 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$12.00
Target (Median)
$12.00
Target Range
$12.00 - $12.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.47
LENZ Therapeutics, Inc. is a biopharmaceutical firm whose primary mission involves the advancement and commercialization of new treatments designed to enhance vision for individuals in the United States. The company's portfolio features two investigational products, LNZ100 and LNZ101, both of which are currently undergoing late-stage Phase III clinical trials as potential solutions for presbyopia. Corporate operations for LENZ Therapeutics are situated in Del Mar, California.